How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Blinatumomab Market
- By Indication: Acute Lymphoblastic Leukemia (ALL), Minimal Residual Disease (MRD) Positive ALL, Relapsed or Refractory B-cell Precursor ALL
- By Patient Population: Adult Patients, Pediatric Patients
- By Line of Therapy: First-line Treatment, Second-line Treatment, Third-line and Beyond
- By Route of Administration: Intravenous Infusion
- By End User: Hospitals, Specialty Oncology Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Acute Lymphoblastic Leukemia (ALL) leads By Indication at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 2 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 242 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.163 →
- 12 Company Profiles 2 players: SWOT & benchmarking p.171 →
Full report · locked preview
Everything inside the Blinatumomab Market report
A complete, evidence-based study - 12 chapters and 101 sections covering market size, segmentation across 5 axes, regional analysis and 2 company profiles, forecast to 2033.
Segmentation covered
Indication 3
Patient Population 2
Line of Therapy 3
Route of Administration 1
End User 2
Companies profiled
Amgen Inc.
Bristol-Myers Squibb Company (Celgene)
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
2 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,947M by 2033 · 5.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Acute Lymphoblastic Leukemia (ALL)63.3
- Minimal Residual Disease (MRD) Positive ALL16.7
- Relapsed or Refractory B-cell Precursor ALL20.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,331M → $2,188M · 6.4%
Europe$927.9M → $1,280M · 4.1%
Asia Pacific$847.3M → $1,163M · 4.0%
Latin America$524.5M → $690.8M · 3.5%
Middle East and Africa$403.5M → $532.0M · 3.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.922026
4.932027
4.942028
4.952029
4.972030
4.972031
5.002032
5.012033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Amgen Inc.53.2
- Bristol-Myers Squibb Company (Celgene)18.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Indication13.0%
Patient Population30.5%
Line of Therapy14.8%
Route of Administration16.2%
End User25.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America37.4
- Europe21.9
- Asia Pacific19.9
- Latin America11.8
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
5 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 90 | 93 | 92 | 96 | 81 | 87 | 90 |
| Bristol-Myers Squibb Company (Celgene) | 78 | 82 | 91 | 93 | 88 | 87 | 87 |
| Market Leader Co | 67 | 66 | 71 | 72 | 81 | 68 | 71 |
| Global Peer Inc | 76 | 73 | 71 | 79 | 79 | 73 | 75 |
| Regional Player | 51 | 73 | 51 | 54 | 59 | 56 | 57 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Amgen Inc.
- Bristol-Myers Squibb Company (Celgene)
- Market Leader Co
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Amgen Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Bristol-Myers Squibb Company (Celgene) | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Market Leader Co | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Global Peer Inc | ✓ | ✓ | − | ✓ | ◐ | ◐ |
| Regional Player | − | ◐ | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Amgen Inc.90
2Bristol-Myers Squibb Company (Celgene)87
3Global Peer Inc75
4Market Leader Co71
5Regional Player57
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Amgen Inc.Bristol-Myers Squibb Company (Celgene)
Challenger2
Strong scale, closing on the leaders.
Market Leader CoGlobal Peer Inc
Contender1
Focused players with pockets of strength.
Regional Player
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Indication in North America, then scale across Blinatumomab Market — a $198M beachhead inside a $2.86B market.
Beachhead (SOM)$198Mobtainable near-term
Serviceable (SAM)$1.08Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Acute Lymphoblastic Leukemia (ALL)
Best fit — highest urgency & budget in Indication.
Economic buyer80 fit
Minimal Residual Disease (MRD) Positive ALL
Strong fit — clear ROI and a fast path to value.
End user68 fit
Relapsed or Refractory B-cell Precursor ALL
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Indication in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Patient Population & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Line of Therapy
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve19%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Indication leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blinatumomab Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified22%
Evaluation14%
Closed-won7%
$13.6KCAC
$51KLTV
3.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Blinatumomab Market is a durable-growth opportunity — $4.30B by 2033, compounding at 9.3%.
TAM · 2025$2.11Btoday
TAM · 2033$4.30Bforecast
CAGR9.3%2027–2033
Cumulative$27.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.30BTotal addressable market
SAM$1.69BServiceable available market
SOM$274MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Indication.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Indication moving from early to mainstream — durable secular demand.
Consolidation upside
2+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.30BLarge & growingTAM by 2033 at 9.3% CAGR
$1.69BServiceable nowreachable with today’s model
$274MBeachhead winobtainable near-term share
2+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.35BBear6.1% CAGR
$4.30BBase9.3% CAGR
$5.50BBull12.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Patient Population optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Blinatumomab Market — a $2.36B market by 2033. Plan: grow share from 8.5% to 14.6%.
Market size · 2033$2.36Btotal addressable
Market CAGR6.7%2027–2033
Target share14.6%from 8.5% today
Revenue ambition$345Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 14.6% | On track |
| Revenue | $200M | $345M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.3% | 44.1% | Ahead |
| Customer retention | 90.0% | 96.0% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Indication
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Patient Population capability
A defensible second engine — invest in Patient Population to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Indication share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Patient Population
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $48M capacity & capability investment
- Greenlight bolt-on M&A in Patient Population
- Authorise North America expansion plan
- Fund R&D program for Indication leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Blinatumomab Market conversation — a $4.59B market you can size, segment and defend in minutes.
Market size · 2033$4.59Btotal opportunity
Growth4.7%CAGR to 2033
Addressable buyers1,786+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Indication
Goal Grow share in Indication
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 3 mopayback period
$97K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
2+players profiled in this market
Coverage includes
Amgen Inc.Bristol-Myers Squibb Company (Celgene)
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blinatumomab Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blinatumomab Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Enteral Nutrition Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportDisintegrating Agent Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportIncretin-Based Drugs Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportMinimally Invasive Neurosurgery Devices Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMicro-ultrasound Systems Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportMicrosclerotherapy Treatment Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCulture Media of Microbiology Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMicrobiology Culture Market
Market size, share, segmentation and regional forecast.
$375M market · 2025 base year
View reportMicrobial Fermentation Technology Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportMeningococcal Disease Drugs Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMeningococcal Disease Treatment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportDrugs for Melanoma Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.